Amarin (AMRN)
(Delayed Data from NSDQ)
$0.60 USD
0.00 (0.32%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.59 -0.01 (-1.44%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
AMRN 0.60 0.00(0.32%)
Will AMRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRN
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Other News for AMRN
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
Affinia Therapeutics appoints Rami Daoud as Chief Business and Financial Officer
Research Highlighting the Clinical Impact of VASCEPA?/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting